almonertinib / eff Cancer Research Results

almon, almonertinib: Click to Expand ⟱
Features:
Aumolertinib (formerly almonertinib; HS-10296)

Almonertinib — an orally bioavailable, covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to preferentially inhibit activating EGFR mutations and the resistance mutation T790M in non-small cell lung cancer (NSCLC). Modality: small-molecule targeted kinase inhibitor. Common naming: almonertinib; aumolertinib (HS-10296); mesilate salt (regional branding varies). Clinically positioned as EGFR-mutant NSCLC therapy with evidence for systemic disease control and clinically relevant CNS activity.

Primary mechanisms (ranked):

  1. Irreversible inhibition of mutant EGFR kinase signaling (Ex19del, L858R, T790M) leading to suppression of oncogenic receptor signaling
  2. Downstream pathway shutdown, especially PI3K–AKT and MAPK/ERK signaling, reducing proliferation/survival signaling
  3. Induction of tumor cell apoptosis secondary to EGFR pathway dependency disruption
  4. Intracranial disease control enabled by pharmacologic CNS exposure (context-dependent)

Bioavailability / PK relevance: Oral, once-daily dosing in clinical use. As a third-generation EGFR-TKI, efficacy is exposure-dependent; clinically meaningful CNS activity has been reported, consistent with blood–brain barrier penetration in preclinical and clinical contexts.

In-vitro vs systemic exposure relevance: Canonical pathway effects (p-EGFR/p-AKT/p-ERK suppression) occur at clinically relevant kinase-inhibition exposures; any reported ROS-driven synergy or redox effects should be treated as combination- and model-dependent rather than a core monotherapy mechanism.

Clinical evidence status: Approved/marketed for EGFR-mutant NSCLC in China (multiple settings) and has positive EU CHMP opinion with defined indications for advanced EGFR-mutant NSCLC; phase III evidence supports first-line efficacy versus gefitinib, and phase II evidence supports post-EGFR-TKI T790M-positive disease activity.

It is mainly used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The drug is designed to overcome resistance to earlier-generation TKIs and to provide a more potent inhibition of EGFR signaling in tumors.

Almonertinib — ranked mechanistic axes and translation constraints

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 EGFR mutant kinase signaling ↓ (oncogene-driven signaling) ↔ to ↓ (wild-type EGFR inhibition typically less dominant than earlier-gen TKIs) P Targeted pathway suppression Core pharmacology: irreversible EGFR inhibition with activity against Ex19del/L858R and T790M; clinical positioning is EGFR-mutant NSCLC.
2 PI3K–AKT survival axis ↓ ↔ (context-dependent) P → R Loss of pro-survival signaling Downstream of EGFR; frequently observed as reduced p-AKT in EGFR-addicted models and aligns with growth inhibition/apoptosis.
3 MAPK/ERK proliferation axis ↓ ↔ (context-dependent) P → R Anti-proliferative signaling shift Common downstream EGFR output; contributes to reduced proliferation and tumor control.
4 Apoptosis execution ↑ ↔ (dose-dependent) R → G Tumor cell death Typically secondary to sustained oncogenic signal withdrawal; caspase/PARP changes are expected in sensitive models.
5 CNS exposure and intracranial control ↓ (intracranial tumor growth, context-dependent) ↔ G Intracranial efficacy enablement Supports use in patients with CNS metastases; mechanistically this is a PK/distribution lever rather than a distinct signaling pathway.
6 ROS / oxidative stress ↔ to ↑ (combination- or model-dependent) ↔ R Secondary stress signaling Not a canonical EGFR-TKI mechanism; reported ROS-mediated synergy in specific combination settings should be treated as contextual.
7 Clinical Translation Constraint Heterogeneous dependence and acquired resistance (context-dependent) On-target toxicities limit exposure (dose-dependent) — Limits durability and tolerability Key constraints include emergence of resistance (e.g., bypass signaling or additional EGFR alterations), CNS vs systemic exposure balance, and class toxicities (rash, lab abnormalities, pneumonitis risk) that can require dose holds/reductions.


eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
5357- almon,    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
- Trial, NSCLC, NA
EGFR↓, eff↝, OS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↝, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:278  Target#:961  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page